Envestnet Asset Management’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Envestnet Asset Management’s Portfolio ONCE Stock Details ONCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-221	Closed	-$19K	–	2997
2018 Q2	$19K	Sell	221 -28	-11%	-$2.16K	﹤0.01%	2439
2018 Q1	$17K	Buy	249 +134	+117%	+$7.74K	﹤0.01%	2414
2017 Q4	$6K	Sell	115 -49	-30%	-$3.52K	﹤0.01%	2731
2017 Q3	$15K	Buy	164 +36	+28%	+$2.73K	﹤0.01%	2539
2017 Q2	$8K	Sell	128 -2	-2%	-$112	﹤0.01%	2759
2017 Q1	$7K	Buy	+130	New	+$7.72K	﹤0.01%	2855

Other funds holding ONCE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Envestnet Asset Management's ONCE Position: Q3 2018 in Review

Envestnet Asset Management sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q3 2018, closing a stake of 221 shares — an estimated $19K sold.

Envestnet Asset Management first reported a position in ONCE in Q1 2017 and held it in 6 quarters. The position peaked at $19K in Q2 2018. 176 funds tracked by Wall St. Rank hold ONCE as of Q3 2018.

Envestnet Asset Management reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
Envestnet Asset Management sold 221 Spark Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $19K.
Envestnet Asset Management first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2017 and held it in 6 quarters.
Envestnet Asset Management's Spark Therapeutics, Inc. Common Stock position peaked at $19K in Q2 2018.
176 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Envestnet Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.